The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep, i am thinking the same thing as well. Surely you would have some sales data as part of a tender pack to go out to bidders to inform them of the success of the product to date or the potential return for them. Though i welcome todays news wholeheartedly , i guess the market still need to start seeing numbers to ascertain the true value of this firm for the share price to do justice to the liberum target price
I think the muted reaction today simply reflects the continued absence of a firm date on which MED3000 will be available to buy. Plus, beyond relatively few people in the investment and medical community, it’s pretty much unknown. These things should change pretty soon.
Futura expects to submit the results of FD71 in September 2022, at which point it will start engaging with potential US ‘partners’. It will have not just those results, but I’d be gobsmacked if it doesn’t by then have early sales data from Europe. As well, by then, the product should be well socialised and discussed on social media and in traditional media. Helping inform this will be the experience of early adopters.
I still feel there’s a determined seller of these shares in the background, through the order book, with their iceberg order, replenishing the order book and selling in round lots. We need much more sustained and determined buying to overcome the weight of these sales, and re-rate the shares. It’s ridiculous that they are still trading at less than a third of Libernum’s estimated value, despite huge progress on the commercial front.
Investors have become Doubting Thomases in the extreme.
Price target update to £1.09...sounds good to me
slowle slowle cache monkey
I was expecting a better reaction with this news. Shows I don't understand the market. But, I'd like to see some updates on the previous contracts they signed as it's been a while. How are the approvals progressing etc.
I know FUM said in the annual results RNS that it could be up to a year before the product came to market, but I'd like to see what are Coopers plans and timelines. I'd also like to see how they plan to market this product.
Talk about underwhelming! But probably because a similar collaboration will happen in the US & may not be the big Pharma’s as predicted! They will want a big slice of the pie and FUM are not willing to give it away for nothing! Good on them but we will see long term! as a small slice of a large pie is potentially bigger than a large slice of a small pie, & I suspect this is the reason for very little movement on the SP!
Finally we get some news of an EU deal ! About time i say , if i am honest with you lot , i was expecting a bigger reaction to the market on this news, oh well! Anyway I like the fact that it is not a bigger distributor based on the shenanigans we have had in the past with them . I love the fact that that Coopers did their own due diligence to confirm FUM clinical findings in their own manner before putting ink to paper. That is now 5 commercial licensing agreements and next stop the submission to the FDA. Cannot wait for Coopers to launch this product this year hopefully for us to finally start sleeping at night !! Well done all long term holders , we seem to finally seeing some things going our way.
Been on the journey for over 12 years and seen many false starts. They have learned from each one and this latest agreement seems to cover off many of the hurdles that caused partneships to fail before. Widely available viagra has raised interest in the benefits of a #### ##### and using a gel which avoids viagra side effects should be incredibly popular! Fingers crossed they have it right this time!!
Yes as has been mentioned why have £ not been disclosed now?
Market is slow to react? Maybe they are not so sure? I think this is a good deal for FUM & Cooper, FUM is not getting stung by a big Pharma again good on them!
Yay!!
Excited or what! I have had the patience of a Saint awaiting Futura's global success & having digested 'Cooper Consumer Health's website ' & seen names and deals through GSK & various other well known names, I reckon we are really onto a winner here NOW. Bet FUM is a riser in the top 5 today.
This reads very well:
"This is our fifth commercial agreement for MED3000, and we are excited to be working with Cooper. Aside from its significant experience and presence within the healthcare field we believe the close strategic alignment of the two companies makes this an excellent partnership and we look forward to working closely together in a long term, profitable and sustainable partnership for both Futura and Cooper."
It seems such a great and in demand product, I can see this really taking off over the next few years. Safer and easier to use than viagra and can be obtained OTC too. Absolute goldmine IMO.
GL.
We now (almost) have the news we have been waiting for. We also now know the reason for the protracted delay - due diligence, in the form of in-house research to validate Futura’s claims. No release date, as “Cooper will be responsible for all launch and marketing expenses”, so that will be down to them. Guess there will be more news soon about this, as the marketing is rolled out. Cooper seems an ideal fit, though not the multi-billion pharma some had hoped Futura would partner with. Whilst it has been growing rapidly, its revenues are still only €500m pa. So, a high-growth product like MED3000 will benefit both parties. Exciting times ahead.